Oral mucositis is a challenging and often painful side effect for many individuals undergoing cancer treatment, particularly chemotherapy. It involves inflammation and ulceration of the lining of the mouth, throat, and sometimes the entire gastrointestinal tract. A recent study has shed light on how the chemotherapy drug 5-Fluorouracil (5-FU) specifically exacerbates oral mucositis, identifying key mechanisms involving inflammation and fibroblast-mediated tissue changes.
For patients and their healthcare providers, understanding the complexities of oral mucositis is crucial. It can significantly impact quality of life, making eating, speaking, and even swallowing difficult. This discomfort can sometimes lead to treatment delays or dose reductions, affecting overall cancer care outcomes. As an Oral Medicine Specialist, Dr. Suhaib Alqudah at Melbourne Oral Medicine focuses on diagnosing and managing such complex oral and maxillofacial conditions, offering secure video consultations Australia-wide.
Oral mucositis is a common and distressing complication of cancer therapy. It manifests as redness, swelling, and painful sores or ulcers inside the mouth. These lesions can range from mild discomfort to severe, debilitating pain, often leading to difficulties with nutrition, hydration, and communication. While various chemotherapy agents and radiation therapy can cause mucositis, the severity and specific characteristics can differ depending on the treatment regimen.
The pain associated with oral mucositis is a significant concern for patients. Managing severe oral pain, regardless of its origin, requires a comprehensive approach. While our understanding of central sensitisation in temporomandibular disorders (TMD) highlights the complexity of chronic pain, the principles of effective pain management are vital for any severe orofacial pain, including that caused by mucositis. (International journal of molecular sciences · 2022; Dental clinics of North America · 2016)
The recent research, published in Nature Scientific Reports, provides a deeper understanding of how 5-Fluorouracil contributes to the severity of oral mucositis. The study indicates that 5-Fluorouracil exacerbates oral mucositis through inflammation and fibroblast-mediated mechanisms. In simpler terms, this means that beyond the general inflammatory response, 5-FU specifically triggers a more intense inflammatory reaction and also influences fibroblasts – cells responsible for producing connective tissue – to create a denser, more rigid tissue structure. This 'fibroblast-mediated mat' contributes to the persistence and severity of the oral lesions, making them more painful and slower to heal. This insight helps us understand why 5-FU related mucositis can be particularly challenging to manage.
Common symptoms of oral mucositis include redness, swelling, burning sensations, and the formation of painful white or yellow ulcers on the cheeks, tongue, gums, and roof of the mouth. Patients may also experience dry mouth (xerostomia), which can further exacerbate discomfort and impact oral health. (Advances in clinical and experimental medicine · 2016; Oral and maxillofacial surgery clinics of North America · 2022)
Red flags that warrant immediate attention include severe pain that interferes with eating or drinking, significant weight loss, signs of infection (fever, pus), or bleeding. If you are undergoing cancer treatment and develop any oral symptoms, it is crucial to communicate with your oncology team promptly. Early intervention can significantly impact the severity and duration of mucositis. For a specialist assessment of persistent or severe oral symptoms, an Oral Medicine consultation can provide expert guidance.
Dr. Suhaib Alqudah, a registered Oral Medicine Specialist with a Doctor of Clinical Dentistry in Oral Medicine and a PhD in Oral Lichen Planus from the University of Melbourne, has extensive experience in managing complex oral conditions. His background includes working at the Royal Dental Hospital of Melbourne and the Peter MacCallum Cancer Centre, providing him with unique insights into the specific oral health challenges faced by cancer patients.
At Melbourne Oral Medicine, we offer secure, Australia-wide online (telehealth) consultations. This service is invaluable for patients experiencing oral mucositis or other oral complications from cancer treatment, as it allows for specialist assessment without the need for travel. During a remote consultation, Dr. Alqudah can:
Our goal is to provide timely, expert care for complex oral mucosal diseases, helping to alleviate discomfort and improve your quality of life during your cancer journey. Dr. Alqudah's expertise in oral mucosal diseases, including conditions like oral lichen planus (Journal of the Formosan Medical Association · 2018; American journal of clinical dermatology · 2024), extends to understanding and managing the broader spectrum of oral health challenges.
While complete prevention can be challenging, strategies such as maintaining excellent oral hygiene, cryotherapy (ice chips) during chemotherapy infusions, and certain medications may help reduce the severity of oral mucositis. Your oncology team can provide specific recommendations tailored to your treatment plan.
The duration of oral mucositis varies depending on the type and intensity of cancer treatment. Symptoms typically appear within days of chemotherapy or radiation and can last for several weeks after treatment concludes. Specialist care can help manage symptoms and promote healing.
Medicare rebates are available for specialist Oral Medicine consultations for eligible patients. Please contact our clinic for more information regarding fees and rebates for telehealth services.
If you or someone you know is experiencing oral mucositis or other complex oral symptoms, we encourage you to reach out. An online consultation with Dr. Suhaib Alqudah can provide the specialist advice and care you need, from anywhere in Australia.
Reference:
Hwang, K.B., Kim, J., Kim, S.Y. et al. 5-Fluorouracil exacerbates oral mucositis through inflammation and fibroblast-mediated mat. Sci Rep 14, 14383 (2024). https://www.nature.com/articles/s41598-026-65299-6
Have a question? Our team can help — book a consultation or explore our services. Book a consultation or explore our services.
Add Comment